Search
Search Constraints
You searched for: Author/Creator Luther, Chelsea- Luther, Chelsea [remove] 2
- 616.33 1
- 616.994 1
- Electronic journals 1
- Gastroenterology -- Periodicals 1
- Gastrointestinal Diseases -- Periodicals 1
- Hematology -- Periodicals 1
- Intestines -- Diseases -- Periodicals 1
- MM metastatic melanoma -- ORR overall response rate -- FDA Food and Drug Administration -- GITR glucocorticoid-induced tumor necrosis factor-related gene receptor -- mAb monoclonal antibody -- CTLA-4 cytotoxic T-lymphocyte-associated antigen-4 -- APCs antigen-presenting cells -- gp100 glycoprotein 100 -- OS overall survival -- DOR prolonged duration of response -- AEs adverse effects -- MAPK mitogen-activated protein kinase -- ERK extracellular-signal-regulated kinase -- SCC squamous cell carcinoma -- PD-1 programmed death 1 -- TVEC talimogene Laherparepvec -- HSV1 herpes-simplex-1 -- GM-CSF granulocyte-macrophage colony-stimulating factor -- COT Cancer Osaka Thyroid -- CDKN2A Cyclin-Dependent Kinase Inhibitor 2A -- DLTs dose-limiting toxicities -- DCR disease-control rate -- ALT alanine aminotransferase -- AST aspartate aminotransferase -- GGT gamma-glutamyl transferase -- CPK creatine phosphokinase -- TNFRSF TNF receptor super family -- Tim-3 T-cell immunoglobulin and mucin containing protein-3 -- IDO indoleamine 2, 3-dioxygenase -- TDO tryptophan 2, 3-dioxygenase -- AHR aryl-hydrocarbon receptor -- CpG cytosine guanine dinucleotide -- ODN oligodeoxyneucelotides -- pDC plamacytoid dendritic cells -- MTD maximum tolerated dose -- CRS cytokine release syndrome -- LAG-3 Lymphocyte activation gene-3 -- NSCLC non-small cell lung cancer -- RCC renal cell carcinoma -- MAP2 microtubule-associated protein 1
- Metastatic melanoma -- Immunotherapy -- Targeted therapy -- Combination therapy -- CTLA-4 -- PD1 -- BRAF -- Ipilimumab -- Vemurafenib -- Dabrafenib -- Nivolumab -- Pembrolizumab -- MEDI4736 -- Talimogene -- TVEC -- Indoleamine 2, 3-dioxygenase -- Indoximod (D-1MT) -- Epacadostat 1
- Oncology -- Periodicals 1